Drugs / REGN846
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01209793 | Nov 2010 → Sep 2011 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01605708 | Jun 2012 → Apr 2013 | atopic eczema | Regeneron Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN846 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01605708 ↗ |
| Known as | SAR302352 | “Intravenously Administered REGN846 (SAR302352)” NCT01209793 ↗ |
| Route | Intravenous | “Intravenously Administered” NCT01209793 ↗ |